Both medications constitute a novel class of protein interventions designed to neutralize the SARS-CoV-2 pathogen . Initially , sotrovimab, engineered by GSK , demonstrated considerable effectiveness https://hamzaenqn742982.mpeblog.com/75042895/sotrovimab-vir-7831-a-deep-exploration-into-the-immunoglobulin-intervention